A team from the University of Geneva and Bayer AG present their findings on the on-off retention of oligonucleotides and the ...

In an effort to bolster drug development in this space, researchers at Thermo Fisher Scientific and the European Pharma Oligonucleotide Consortium published a consensus article in February on best ...

“It’s amazing how rapidly this has developed from basic research to a class of drugs that has achieved clinical success,” says Arthur Krieg, who studies oligonucleotide drugs at the RNA ...

Lung cancer is one of the leading causes of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about ...

The global Oligonucleotide CDMO Market, valued at US$2.33 billion in 2023, is forecasted to grow at a robust CAGR of 21.8%, ...

GSK has set its sights on dominance of the market for hepatitis B virus (HBV) therapeutics, licensing an antisense oligonucleotide drug from Arrowhead Pharma and Johnson & Johnson that had been ...

Therapeutic synthetic oligonucleotides face unique analytical challenges in late-stage development. Meeting stringent regulatory requirements demands highly specific and sensitive methods like LC-MS.

Notably, TOF-MS can provide simultaneous identification and sequence confirmation for drug substances as well as impurities/metabolites. In this webinar, a novel LC-MS/MS Q-TOF instrument (ZenoTOF ...